Chronic benzodiazepine administration
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
Clinical studies suggest that carbamazepine may attenuate effects of alprazolam discontinuation. Since discontinuation of chronic alprazolam in a mouse model is associated with behavioral alterations and upregulation at the gamma-aminobutyric acidA (GABAA) receptor, we studied the effects of carbamazepine administration after alprazolam (2 mg/kg/day) discontinuation. Open-field activity was increased in mice 4 days after alprazolam discontinuation, but this effect was reduced significantly by continuous infusion of carbamazepine, 25 or 100 mg/kg/day. Benzodiazepine receptor binding in vivo was increased in cortex at 2 and 4 days after alprazolam discontinuation, and in hypothalamus at 4 days; with carbamazepine, 100 mg/kg/day, binding in both regions at these time points was similar to control values. Similar results were observed in cortex with benzodiazepine receptor binding in vitro. GABA-dependent chloride uptake was also increased at 4 days alprazolam administration. Treatment with carbamazepine attenuated (P less than 0.10) this increase. Carbamazepine alone after vehicle did not alter benzodiazepine binding or GABA-dependent chloride uptake. These results indicate that carbamazepine administration after alprazolam discontinuation attenuates behavioral and neurochemical alterations associated with discontinuation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Effects of alprazolam discontinuation on benzodiazepine binding in vivo. Binding was determined by uptake of [³H]Ro15-1788. Results are means ± SEM, N = 6-10 for each group. ALP/VEH = alprazolam for 7 days followed by vehicle for 7 days; VEH/ČBP = vehicle for 7 days followed by carbamazepine, 100 mg/kg/day, for 7 days; ALP/CBP = alprazolam for 7 days followed by carbamazepine for 7 days. Key: (*) P < 0.05 for ALP/ VEH at days 2 or 4 vs day 1.](https://figures.cochat.ai/paper-figures/d8e27f6135e44eafa18e0f043b705c21/chronic-benzodiazepine-administration-figure-2.png)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Alprazolam use for merely 1 week produces discontinuation symptoms in mice (Galpern et al., 1991)”
From A Review of Alprazolam Use, Misuse, and Withdrawal (2018) · cites this paper as Galpern et al., 1991
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sequence and functional expression of the GABAA receptor shows a ligand-gated receptor super-family
Schofield, P. R., Darlison, M. G., Fujita, N., Burt, D. R., Stephenson, F. A., Rodriguez, H., Rhee, L. M., Ramachandran, J., Reale, V., Glencorse, T. A., et al. (1987) · Nature · doi:10.1038/328221a0 · Cited by 1,622
Benzodiazepine receptors in rat brain
SQUIRES, R. F., & BRAESTRUP, C. (1977) · Nature · doi:10.1038/266732a0 · Cited by 1,449
A practical computer-based approach to the analysis of radioligand binding experiments
McPherson, G. A. (1983) · Computer Programs in Biomedicine · doi:10.1016/0010-468x(83)90031-4 · Cited by 829
Current Status of Benzodiazepines
Koch-Weser, J., Greenblatt, D. J., Shader, R. I., & Abernethy, D. R. (1983) · New England Journal of Medicine · doi:10.1056/nejm198308183090705 · Cited by 451
Long-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332
Abuse liability of benzodiazepines.
Woods, J. H., Katz, J. L., & Winger, G. (1987) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06658-x · Cited by 315
Chronic benzodiazepine treatment decreases postsynaptic GABA sensitivity
Gallager, D. W., Lakoski, J. M., Gonsalves, S. F., & Rauch, S. L. (1984) · Nature · doi:10.1038/308074a0 · Cited by 280
Dependence, Tolerance, and Addiction to Benzodiazepines: Clinical and Pharmacokinetic Considerations
Greenblatt, D. J., & Shader, R. I. (1978) · Drug Metabolism Reviews · doi:10.3109/03602537808993775 · Cited by 229
Miller, L. G., Greenblatt, D. J., Barnhill, J. G., & Shader, R. I. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20998-3 · Cited by 220
Kornecki, E., Ehrlich, Y. H., & Lenox, R. H. (1984) · Science · doi:10.1126/science.6150550 · Cited by 210
Research works printed but not linked: 1
- MacDonald, 1988, Antiepileptic drug actions discussion, Epilepsia, S19
Cited by
A Review of Alprazolam Use, Misuse, and Withdrawal
Ait-Daoud, N., Hamby, A. S., Sharma, S., & Blevins, D. (2018) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000350 · Cited by 195
Benzodiazepines Remain Important Therapeutic Options in Psychiatric Practice
Dubovsky, S. L., & Marshall, D. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000524400 · Cited by 171
Galpern, W. R., Lumpkin, M., Greenblatt, D. J., Shader, R. I., & Miller, L. G. (1991) · Psychopharmacology · doi:10.1007/bf02244183 · Cited by 97
Effect of gabapentin (neurotonin®) on mood and well-being in patients with epilepsy
Dimond, K. R., Pande, A. C., LaMoreaux, L., & Pierce, M. (1996) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(96)00005-x · Cited by 55
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.12.1760 · Cited by 44
Metadata
- Authors
- Galpern, W. R., Miller, L. G., greenblatt, D. J., Szabo, G. K., Browne, T. R., & Shader, R. I.
- Affiliations
- Boston University (US)
- Tufts University (US)
- Corresponding author
- Miller, Lawrence G.
- Venue
- Biochemical Pharmacology
- Publisher
- Elsevier BV
- Published
- 1991-12
- Volume
- 42
- Pages
- S99-S104
- ISSN
- 0006-2952 (ISSN-L)
- OpenAlex
- W1527089640
- Cited by
- 17
- References
- 50
- Citations by year
- 2023: 1 · 2022: 1 · 2021: 1 · 2017: 1
- FWCI
- 0.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 4372 d)
- Locations
- Biochemical Pharmacology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service
- National Institute on Aging (AG-01-006)
- National Institute of Mental Health (MH 34223)
- National Institute on Drug Abuse (DA05258)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- carbamazepine, alprazolam, benzodiazepine withdrawal, benzodiazepine discontinuation, benzodiazepine binding, open field behavior
- MeSH terms
- Alprazolam, Animals, Anxiety, Carbamazepine, Cerebral Cortex, Disease Models, Animal, Drug Administration Schedule, Drug Evaluation, Preclinical, Hippocampus, Hypothalamus, Male, Motor Activity, Receptors, GABA-A, Seizures, Substance Withdrawal Syndrome, Time Factors, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chronic benzodiazepine administration. https://app.cochat.ai/papers/10.1016/0006-2952(91)90398-o
- The paper
- Galpern, W. R., Miller, L. G., greenblatt, D. J., Szabo, G. K., Browne, T. R., & Shader, R. I. (1991). Chronic benzodiazepine administration. Biochemical Pharmacology. https://doi.org/10.1016/0006-2952(91)90398-o
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.